StockNews.com Initiates Coverage on Curis (NASDAQ:CRIS)

StockNews.com began coverage on shares of Curis (NASDAQ:CRIS) in a research note issued to investors on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Curis in a report on Tuesday, December 10th.

Curis Price Performance

CRIS opened at $2.63 on Thursday. Curis has a one year low of $2.57 and a one year high of $17.49. The business has a 50 day simple moving average of $3.24 and a two-hundred day simple moving average of $4.12. The firm has a market capitalization of $22.27 million, a price-to-earnings ratio of -0.34 and a beta of 3.49.

Hedge Funds Weigh In On Curis

Hedge funds and other institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC purchased a new position in shares of Curis during the fourth quarter valued at about $35,000. Millennium Management LLC increased its position in shares of Curis by 92.6% during the fourth quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 12,287 shares during the period. Focused Wealth Management Inc increased its position in shares of Curis by 9.5% during the fourth quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock valued at $181,000 after buying an additional 5,138 shares during the period. Geode Capital Management LLC increased its position in shares of Curis by 27.3% during the fourth quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock valued at $254,000 after buying an additional 17,820 shares during the period. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Curis during the fourth quarter valued at about $607,000. Hedge funds and other institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.